In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
Binding of growth factors and cytokines to their cognate receptors on cell membranes triggers their endocytosis and degradation in lysosomes, thus providing a physiologically important negative feedback mechanism for cell signalling.
The ESCRT-II complex recognizes ubiquitinated receptors in the endosomal membrane, thus initiating their sorting to degradative lysosomes. (click to enlarge image)It is not known in detail how endocytosed receptors are trafficked to the degradative lysosomes, but work in Harald StenmarkÂ’s lab has uncovered several factors involved in this process. Among these are the so-called endosomal sorting complexes required for transport (ESCRTs), and Thomas Slagsvold in StenmarkÂ’s group has previously shown that the so-called GLUE domain in the ESCRT-II complex binds ubiquitin .
In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
From major journals, first or last author from the Institute for Cancer Research
Trachsel-Moncho L, Mathai BJ, Veroni C, Simonsen A(2025) SNX10 at the crossroad of endocytosis and piecemeal mitophagy Autophagy, 1-3(in press) DOI 10.1080/15548627.2025.2499641, PubMed 40327657
Hektoen HH, Tsuruda KM, Brustugun OT, Neumann K, Andreassen BK(2025) Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50 ESMO Open, 10(5), 105073(in press) DOI 10.1016/j.esmoop.2025.105073, PubMed 40305908
Dillard C, Teles-Reis J, Jain A, Antunes MG, Ruiz-Duran P, Qi Y, Le Borgne R, Jasper H, Rusten TE(2025) NF-κB signaling driven by oncogenic Ras contributes to tumorigenesis in a Drosophila carcinoma model PLoS Biol, 23(4), e3002663 DOI 10.1371/journal.pbio.3002663, PubMed 40294135
Garcia-Foncillas J, Bayle A, Arnold D, Avouac B, Awada A, de la Cruz-Merino L, Helland Ã…, Lassen U, Laurent-Puig P, Normanno N, Rohrberg K, Taieb J, Stenzinger A(2025) Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access Future Oncol, 1-8(in press) DOI 10.1080/14796694.2025.2501523, PubMed 40340714
Trachsel-Moncho L, Mathai BJ, Veroni C, Simonsen A(2025) SNX10 at the crossroad of endocytosis and piecemeal mitophagy Autophagy, 1-3(in press) DOI 10.1080/15548627.2025.2499641, PubMed 40327657
Rosenberger L, Hansmann L, Anastasopoulou V, Wolf SP, Drousch K, Moewes C, Feng X, Cao G, Huang J, Yew PY, Strønen E, Kato T, Saligrama N, Olweus J, Nakamura Y, Willimsky G, Blankenstein T, Schreiber H, Leisegang M(2025) Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire J Immunother Cancer, 13(5) DOI 10.1136/jitc-2024-011351, PubMed 40316304